Ascendis Pharma A/S reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was EUR 6.16 million compared to EUR 1.02 million a year ago. Net loss was EUR 81.32 million compared to EUR 134.37 million a year ago. Basic loss per share from continuing operations was EUR 1.46 compared to EUR 2.5 a year ago.
For the six months, sales was EUR 12.99 million compared to EUR 1.77 million a year ago. Net loss was EUR 206.82 million compared to EUR 197.17 million a year ago. Basic loss per share from continuing operations was EUR 3.68 compared to EUR 3.66 a year ago.